Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Restasis

U.S. Judge in Texas Invalidates Allergan Patents on Restasis

Jan Wolfe & Michael Erman  |  October 18, 2017

(Reuters)—A U.S. judge invalidated patents on Allergan Plc’.s dry eye medicine Restasis on the grounds that the patents cover obvious ideas, a decision that drove the pharmaceutical company’s shares down more than 6%. Judge William Bryson issued the ruling in federal court in Marshall, Texas, in a longstanding dispute between Allergan and generic drugmakers led…

Filed under:Legal UpdatesProfessional Topics Tagged with:drugEye diseaseLegalRestasis

Sjögrens Syndrome: The Need to Bridge Patient Symptoms & Objective Findings

New Discoveries in Sjögren’s Disease

Vanessa Caceres  |  June 1, 2025

Although dryness and other symptoms of Sjögren’s disease continue to vex patients, the prospect of new treatments and a recent name change demonstrate advances in patient care.

Filed under:ConditionsSjögren’s Disease Tagged with:ACR on AirACR on Air podcastDry eyeeyemouthpatient careSjogren'sskin

Cliff Diving: Evergreening & Other Oddities

Philip Seo, MD, MHS  |  September 5, 2022

The glassblowers were in revolt. The island of Murano, in the 13th century, was a perfect home for the glassblowing industry. Connected to Venice through a system of bridges, Murano was surrounded by waters that protected the city from the furnaces that fueled the glassblowers’ craft. The Republic of Venice dominated trade throughout the Mediterranean,…

Filed under:EthicsOpinionProfessional TopicsRheuminationsSpeak Out Rheum Tagged with:drug patentsevergreeninggene patentgeneric drugs

New Options for Patients with Concurrent Dry Eye & Rheumatic Disease

Vanessa Caceres  |  May 18, 2019

Dry eye affects at least 30 million people in the U.S. and many more around the globe. Among patients with autoimmune disease—including Sjögren’s syndrome and rheumatoid arthritis—that number can climb even higher. Although dry eye may sound like just an annoyance, it can range from mildly irritating to debilitating, depending on the extent of the…

Filed under:Conditions Tagged with:autologous serum tearslifitegrastTrueTear

U.S. Supreme Court Rejects Allergan Bid to Use Tribe to Shield Drug Patents

Lawrence Hurley  |  April 16, 2019

WASHINGTON (Reuters)—The U.S. Supreme Court has cast aside pharmaceutical company Allergan Plc.’s unorthodox bid to shield patents from a federal administrative court’s review by transferring them to a Native American tribe. The justices left in place a lower court ruling upholding the authority of a U.S. Patent and Trademark Office tribunal to decide the validity…

Filed under:Drug Updates Tagged with:Allergan Plc tribal patent dealAllergan Plc.LegalNative American tribeNew York Saint Regis Mohawk TribeRestasis

U.S. Congress to Hold Hearing on Allergan Tribal Patent Deal

Jan Wolfe  |  November 3, 2017

(Reuters)—A U.S. House of Representatives subcommittee on Thursday called a November 7 hearing on the legitimacy of an agreement between drugmaker Allergan Plc and a Native American tribe intended to shield patents from administrative review. The House Judiciary Committee’s subcommittee on intellectual property, chaired by Republican Representative Darrell Issa of California, said in a statement…

Filed under:Legal Updates Tagged with:Allergan Plc tribal patent dealAllergan Plc.New York Saint Regis Mohawk TribeNovember 7 hearingU.S. House of Representatives subcommittee

Senator McCaskill Drafts Bill in Response to Allergan Patent Maneuver

Michael Erman  |  October 5, 2017

NEW YORK (Reuters)—Democratic U.S. Senator Claire McCaskill on Thursday said she drafted a bill stating that tribal sovereign immunity cannot be used to block U.S. Patent and Trademark Office review of a patent. Drugmaker Allergan Plc made a deal to transfer some of its patents to a Native American tribe two weeks ago in order…

Filed under:Uncategorized Tagged with:Allergan Plc dealAllergan Plc.tribal sovereign immunity

U.S. House Committee Launches Probe of Allergan Patent Deal

Michael Erman  |  October 4, 2017

NEW YORK (Reuters)—A U.S. House of Representatives committee launched a probe into drugmaker Allergan Plc’s deal to transfer some of its patents to a Native American tribe to shield them from review. A bipartisan group of four representatives from the House Oversight and Government Committee, including Republican Chairman Trey Gowdy and top Democrat Elijah Cummings,…

Filed under:Legal Updates Tagged with:Allergan Plc dealNative American tribeRestasisSaint Regis Mohawk TribeU.S. House of Representatives committee

U.S. Tribal Patent Deal Could Impact Generic Drug Market

Jan Wolfe  |  September 12, 2017

(Reuters)—A groundbreaking deal between Allergan Plc. and a Native American tribe to shield the company’s patents in administrative proceedings could also be used be to protect them from challenges in federal court, legal experts say, potentially dealing a blow to generic competition. Allergan said on Friday it had transferred patents on its blockbuster dry eye…

Filed under:Drug UpdatesLegal Updates Tagged with:Allergan Plc.generic competitiongeneric drugsLegalRestasis

Pfizer to Buy Allergan in $160 Billion Deal

Ransdell Pierson & Bill Berkrot  |  November 24, 2015

NEW YORK (Reuters)—Pfizer Inc. on Monday said it would buy Botox maker Allergan Plc. in a deal worth $160 billion to slash its U.S. tax bill, rekindling a fierce political debate over the financial maneuver. The acquisition, which would shift Pfizer’s headquarters to Ireland, would be the biggest-ever tax inversion. The news prompted Democratic presidential…

Filed under:Drug Updates Tagged with:Allergan Plc.mergerPfizer Inc.pharmaceutical company

  • 1
  • 2
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences